Summary
BioMarin Pharmaceutical has announced its acquisition of Amicus Therapeutics in an all-cash deal worth $4.8 billion. This deal is expected to close between April and June of next year and has unanimous support from both companies’ boards. BioMarin expects Amicus’ rare disease drugs to increase its revenue growth through 2030 and beyond.

Access impact
The acquisition of Amicus by BioMarin is expected to have a positive impact on the company’s long-term revenue growth. Amicus brings two marketed drugs for rare diseases, Galafold and a combination of Pombiliti and Opfolda, which generated $371 million and $77 million respectively in the first nine months of this year. This acquisition will also add a potentially first-of-its-kind treatment for a rare kidney disease to BioMarin’s portfolio.

Top-3 domain lens
Clinical Effectiveness
Amicus’ rare disease drugs, Galafold and Pombiliti/Opfolda, have shown to be effective in treating Fabry disease and late-onset Pompe disease, respectively. This acquisition will add to BioMarin’s already impressive list of 10 marketed therapies.

Budget Impact and Resources
The deal, worth $4.8 billion, is expected to be accretive to BioMarin’s non-GAAP diluted earnings per share within a year of its closing. This acquisition will also give BioMarin access to Amicus’ resources and scale, allowing them to reach more patients with rare diseases.

Cost-Effectiveness
The acquisition of Amicus is a strategic fit for BioMarin, as it diversifies their portfolio and adds potential blockbuster drugs to their pipeline. However, the large price tag and potential peak sales of Amicus’ drugs may be a cause for concern for some investors.

Hashtags
#MarketAccessRiskAssessment #Pricing #Reimbursement #MarketAccess #MARArating #Company #Drug #RegulatoryAgency

CTA
Explore 350+ independent assessments: https://mararating.com/mara-ratings-list

Source
source: https://www.biopharmadive.com/news/biomarin-amicus-deal-acquisition-rare-disease-drugs/808382/